Financial Comparison: AzurRx BioPharma (AZRX) and Its Competitors

AzurRx BioPharma (NASDAQ: AZRX) is one of 104 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare AzurRx BioPharma to similar companies based on the strength of its profitability, analyst recommendations, risk, dividends, valuation, institutional ownership and earnings.


This table compares AzurRx BioPharma and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
AzurRx BioPharma N/A -470.85% -205.40%
AzurRx BioPharma Competitors -2,433.09% -68.81% -8.77%

Analyst Recommendations

This is a breakdown of recent ratings and target prices for AzurRx BioPharma and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AzurRx BioPharma 0 0 1 0 3.00
AzurRx BioPharma Competitors 904 3898 6891 184 2.54

AzurRx BioPharma presently has a consensus target price of $8.00, indicating a potential upside of 119.78%. As a group, “Pharmaceuticals” companies have a potential upside of 19.19%. Given AzurRx BioPharma’s stronger consensus rating and higher probable upside, equities research analysts plainly believe AzurRx BioPharma is more favorable than its competitors.

Earnings & Valuation

This table compares AzurRx BioPharma and its competitors gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
AzurRx BioPharma N/A -$14.59 million -2.53
AzurRx BioPharma Competitors $8.31 billion $1.11 billion 159.04

AzurRx BioPharma’s competitors have higher revenue and earnings than AzurRx BioPharma. AzurRx BioPharma is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

8.2% of AzurRx BioPharma shares are held by institutional investors. Comparatively, 44.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 9.1% of AzurRx BioPharma shares are held by company insiders. Comparatively, 11.3% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.


AzurRx BioPharma competitors beat AzurRx BioPharma on 8 of the 12 factors compared.

About AzurRx BioPharma

AzurRx BioPharma, Inc. is a clinical development-stage biopharmaceutical company. The Company is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The Company’s product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101. MS1819 is an acid-resistant secreted lipase produced by Yarrowia lipolytica, known as LIP2, that the Company is developing through recombinant deoxyribonucleic acid (DNA) technology for the treatment of exocrine pancreatic insufficiency (EPI), associated with chronic pancreatitis (CP) and cystic fibrosis (CF). AZX1101 is a recombinant-lactamase combination of bacterial origin under development for the prevention of hospital-acquired infections by resistant bacterial strains induced by parenteral administration of b-lactam antibiotics (known as nosocomial infections), as well as the prevention of antibiotic-associated diarrhea (AAD).

Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply